Oncolytics Biotech Advances Pelareorep Trial for Pancreatic Cancer Treatment Potential

Oncolytics Biotech Pushes Forward with Promising Pancreatic Cancer Trial

Oncolytics Biotech Inc., a clinical-stage immunotherapy company, announces a significant update regarding its registration-directed clinical trial for pelareorep, a double-stranded RNA immunotherapeutic agent, aimed at treating first-line pancreatic ductal adenocarcinoma (PDAC). The company plans to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to discuss the study's detailed design. This trial is pivotal as it involves a three-arm approach where patients will be randomized to receive either the standard treatment of Gemcitabine and nab-paclitaxel (GnP), or GnP combined with pelareorep, or GnP along with pelareorep and a checkpoint inhibitor (CPI). The primary endpoint is Overall Survival (OS), with expectations of achieving statistical significance over the control arm.

The design of this clinical trial is particularly noteworthy, as it includes an interim efficacy analysis, which allows for early assessments of clinical benefits. Notably, a post-hoc analysis has shown that the combination of pelareorep with chemotherapy results in a two-year survival rate of 22%, compared to just 9% for chemotherapy alone. This promising data underscores the potential of pelareorep to enhance treatment outcomes for patients suffering from this aggressive form of cancer. Oncolytics Biotech's CEO, Jared Kelly, expresses optimism about the study's advancement, highlighting the transformative potential of pelareorep as a leading immunotherapy option for first-line pancreatic cancer patients.

The broader implications of Oncolytics' advancements extend beyond pancreatic cancer. The company is also exploring pelareorep in conjunction with chemotherapy and checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. This strategic focus on combining treatments is designed to activate immune responses, transforming "cold" tumors into "hot" ones, thereby improving the efficacy of existing therapies. Furthermore, Oncolytics is actively pursuing strategic partnerships to enhance the development of pelareorep and maximize its commercial potential, reflecting the company's commitment to innovation in oncology and improving patient outcomes.

In summary, Oncolytics Biotech is poised to make significant strides in the treatment of pancreatic cancer with its upcoming clinical trial for pelareorep. The innovative trial design and promising preliminary results demonstrate the company's dedication to advancing immunotherapy solutions. As Oncolytics continues to navigate the regulatory landscape and seek collaborations, the potential for pelareorep to become a groundbreaking treatment option remains a focal point for the company’s future.